A Phase 4 interventional study of Palonosetron and Dexamethason and Palonosetron in Postoperative Nausea and Vomiting, sponsored by Bangladesh Medical University. Completed at 1 site in Bangladesh. Open to female participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-09-10.
Sponsored by Bangladesh Medical University · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Postoperative nausea and vomiting (PONV) is a common complication after general anaesthesia, especially among female patients undergoing laparoscopic surgery. This randomized controlled trial evaluates whether combined palonosetron and dexamethasone is more effective than palonosetron alone in preventing postoperative nausea and vomiting after gynaecological laparoscopic surgery.
Eligible patients will be randomized into two parallel groups. The intervention group will receive palonosetron plus dexamethasone, while the comparator group will receive palonosetron alone. Patients will be followed for 24 hours after surgery for incidence and severity of nausea and vomiting, rescue antiemetic requirement, adverse effects, patient satisfaction, and haemodynamic parameters.
Postoperative nausea and vomiting (PONV) is a common and distressing complication following general anaesthesia, particularly among female patients undergoing laparoscopic surgical procedures. Although several medications are available for prevention of PONV, no single agent completely eliminates the risk because multiple physiological and surgical factors contribute to its development.
Palonosetron is a second-generation serotonin (5-hydroxytryptamine-3 or 5-HT3) receptor antagonist with a prolonged duration of action and strong receptor affinity. It reduces nausea and vomiting by blocking serotonin-mediated pathways involved in the vomiting reflex. Dexamethasone, a corticosteroid with antiemetic properties, has also been shown to enhance the effectiveness of other antiemetic medications through multiple mechanisms, including modulation of inflammatory pathways and enhancement of antiemetic receptor sensitivity.
This randomized controlled trial is designed to evaluate whether adding dexamethasone to palonosetron provides improved prevention of postoperative nausea and vomiting compared with palonosetron alone in patients undergoing gynaecological laparoscopic surgery under general anaesthesia.
Participants will be randomly assigned to receive either combined palonosetron and dexamethasone or palonosetron alone before induction of anaesthesia. All participants will undergo standardized anaesthetic management and postoperative monitoring. The study will assess the effectiveness and safety of these preventive strategies during the postoperative period.
The findings of this study may provide additional evidence regarding the role of combination antiemetic therapy in improving postoperative recovery, patient comfort, and satisfaction after laparoscopic gynaecological procedures. The results may contribute to optimizing perioperative care practices and improving the management of patients at risk of postoperative nausea and vomiting.
638 studies on the registry are indexed under Postoperative Nausea and Vomiting; 110 are open to participants now.
This study's enrollment of 76 is below the median of 112 across 529 interventional studies indexed under Postoperative Nausea and Vomiting.
Browse Postoperative Nausea and Vomiting studies →Bangladesh Medical University is the lead sponsor of 45 studies on the registry; 27 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive palonosetron 0.075 mg IV combined with dexamethasone 5 mg IV before induction of general anaesthesia.
Drug: Palonosetron and Dexamethason
Participants receive palonosetron 0.075 mg IV before induction of general anaesthesia
Drug: Palonosetron
Participants receive palonosetron 0.075 mg IV combined with dexamethasone 5 mg IV before induction of general anaesthesia.
Participants receive palonosetron 0.075 mg IV before induction of general anaesthesia.
Incidence of postoperative nausea and vomiting
Occurrence of nausea and vomiting episodes during the postoperative period (0-24 hours).
Time frame: 24 hours after surgery
Severity of postoperative nausea and vomiting
Severity of nausea and vomiting will be assessed using the Visual Analogue Scale (VAS), where 0 indicates no nausea and 10 indicates the worst possible nausea. The severity will be evaluated and compared between the two study groups during the postoperative period.
Time frame: 1 hour, 3 hours, 6 hours, 12 hours, and 24 hours after surgery
Requirement of rescue antiemetic medication
The requirement for rescue antiemetic medication will be recorded and compared between groups. Patients experiencing significant nausea or vomiting (VAS score ≥4) will receive rescue antiemetic treatment with intravenous metoclopramide 10 mg, and the total requirement will be documented.
Time frame: During the first 24 hours after surgery
Incidence of adverse effects related to study drugs
Drug-related adverse effects, including dizziness, headache, and arrhythmia, will be monitored and compared between the study groups using a four-point severity scale.
Time frame: During the first 24 hours after surgery
Patient satisfaction after surgery
Patient satisfaction regarding postoperative recovery and nausea-vomiting management will be assessed using a 5-point Likert satisfaction scale, where 1 indicates very dissatisfied, and 5 indicates very satisfied. Higher scores indicate greater patient satisfaction. The satisfaction scores will be compared between the two study groups.
Time frame: At 24 hours after surgery
Postoperative systolic blood pressure (SBP)
Systolic blood pressure will be measured and compared between the palonosetron-dexamethasone group and the palonosetron alone group during the postoperative period.
Time frame: At 1, 6, 12, and 24 hours after surgery
Postoperative diastolic blood pressure (DBP)
Diastolic blood pressure will be measured and compared between the study groups during postoperative follow-up.
Time frame: At 1, 6, 12, and 24 hours after surgery
Postoperative mean arterial pressure (MAP)
Mean arterial pressure will be recorded and compared between the two study groups during the postoperative period.
Time frame: At 1, 6, 12, and 24 hours after surgery
Postoperative heart rate (HR)
Heart rate will be monitored and compared between the palonosetron-dexamethasone group and the palonosetron alone group after surgery.
Time frame: At 1, 6, 12, and 24 hours after surgery
Postoperative oxygen saturation (SpO₂)
Peripheral oxygen saturation (SpO₂) will be measured using pulse oximetry and compared between the two study groups during postoperative follow-up.
Time frame: At 1, 6, 12, and 24 hours after surgery
Plan to share: No
Ran from Sep 2025 to primary completion in May 2026, 8 months.
Of 67 non-industry phase 4 interventional studies under Postoperative Nausea and Vomiting, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's 8 months is below that.
Counting every sponsor, half of 67 studies reached it within 11 months; a quarter within 5 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Postoperative Nausea and Vomiting →
Bangladesh Medical University